Key takeaways
- Semaglutide is a modified GLP-1 that activates the GLP-1 receptor; tirzepatide is a single peptide based on GIP that activates both the GIP and GLP-1 receptors. Both carry a fatty diacid side chain that binds albumin.
- Novo Nordisk makes semaglutide (Ozempic, Rybelsus, Wegovy; first US approval December 2017); Eli Lilly makes tirzepatide (Mounjaro, Zepbound; first US approval May 2022).
- SURMOUNT-5 (NEJM, 2025) randomised 751 adults with obesity, without type 2 diabetes, to either drug for 72 weeks, open-label and funded by Eli Lilly; its primary measure was the percent change in weight.
- The US labels for both carry a boxed warning on thyroid C-cell tumours in rodents, with human relevance not determined, and overlapping warnings on pancreatitis, gallbladder disease and kidney injury.
- FDA declared both US shortages resolved (tirzepatide December 2024, semaglutide February 2025), and WADA has both on its 2027 Monitoring Program; neither is named on the 2027 Prohibited List.
01How do semaglutide and tirzepatide differ?
The same questions for both, from the labels and regulators’ records, dated 18 November 2026.
| Question | Semaglutide | Tirzepatide |
|---|---|---|
| What it is | A GLP-1 receptor agonist: a modified version of the hormone GLP-1, with a C-18 fatty diacid side chain | A GIP receptor and GLP-1 receptor agonist: one peptide based on the GIP sequence, with a C-20 fatty diacid side chain |
| Formula and mass | C187H291N45O59; 4113.58 g/mol | C225H348N48O68; 4813.53 Da |
| Maker | Novo Nordisk | Eli Lilly |
| US brand names | Ozempic, Rybelsus, Wegovy | Mounjaro, Zepbound |
| First US approval | Ozempic, 5 Dec 2017 | Mounjaro, 13 May 2022 |
| US label uses | Type 2 diabetes; cardiovascular risk in type 2 diabetes; kidney outcomes in type 2 diabetes with chronic kidney disease; excess body weight (adults, ages 12+); cardiovascular risk in cardiovascular disease with obesity or overweight; MASH (accelerated approval) | Type 2 diabetes (adults, children 10+); cardiovascular risk in type 2 diabetes; excess body weight (adults); moderate to severe obstructive sleep apnoea with obesity |
| European Union | Ozempic (2018), Rybelsus (2020), Wegovy (2022), Kayshild (2026) | Mounjaro (2022): type 2 diabetes and weight management |
| United Kingdom | Ozempic, Rybelsus, Wegovy; prescription-only (POM) | Mounjaro; prescription-only (POM) |
| Australia | Schedule 4; Ozempic on the ARTG since 28 Aug 2019 | Schedule 4; Mounjaro on the ARTG since 23 Dec 2022 |
| US boxed warning | Thyroid C-cell tumours in rodents; human relevance “has not been determined” | Thyroid C-cell tumours in rats; human relevance “has not been determined” |
| Outcome trials on the US labels | SUSTAIN 6, SELECT and FLOW, each against placebo | SURPASS-CVOT, against dulaglutide |
| US shortage declared resolved | 21 Feb 2025 | 19 Dec 2024 |
| Sport (WADA) | 2027 Monitoring Program; not named on the 2027 Prohibited List | 2027 Monitoring Program; not named on the 2027 Prohibited List |
Brand names appear here only as facts from the labels. Research-grade material sold under either name is none of these medicines, and this page does not describe it.
02What is semaglutide?
Semaglutide is a modified version of GLP-1 (glucagon-like peptide-1), a hormone the body releases after eating. Its US label gives it 94% sequence homology to human GLP-1 and says it “selectively binds to and activates the GLP-1 receptor”. A C-18 fatty diacid lets it bind albumin, a blood protein. Novo Nordisk makes it. Labels, trials and status in full: what is semaglutide?
03What is tirzepatide?
Tirzepatide is a single peptide that its US label says “is based on the GIP sequence” and “selectively binds to and activates both the GIP and GLP-1 receptors”. GIP is glucose-dependent insulinotropic polypeptide, a second gut hormone. A C-20 fatty diacid lets it bind albumin. Eli Lilly makes it. Labels, trials and status in full: what is tirzepatide?
04What research compared semaglutide and tirzepatide directly?
Two phase 3 trials with published results compared the two drugs directly, both funded by Eli Lilly, tirzepatide’s maker (ClinicalTrials.gov and PubMed, searched 18 November 2026 under both names, their development codes and brand names). We report each design and what the paper reports for its primary measure.
| SURPASS-2 | SURMOUNT-5 | |
|---|---|---|
| Paper | Frías et al., NEJM, 2021 | Aronne et al., NEJM, 2025 |
| Registry | NCT03987919 | NCT05822830 |
| Who took part | 1,879 adults with type 2 diabetes | 751 adults with obesity, without type 2 diabetes |
| Design | Open-label, randomised 1:1:1:1 to one of three tirzepatide levels or semaglutide at one level; phase 3 | Open-label, randomised 1:1 to tirzepatide or semaglutide, each at the highest level a participant tolerated; phase 3b |
| Length | 40 weeks | 72 weeks |
| Primary measure | Change in HbA1c, a measure of average blood sugar, from baseline to week 40 | Percent change in weight from baseline to week 72 |
| What the paper reports for the primary measure | Mean change in HbA1c of −2.01 to −2.30 percentage points across the three tirzepatide levels, and −1.86 with semaglutide | Least-squares mean change of −20.2% (95% CI −21.4 to −19.1) with tirzepatide and −13.7% (95% CI −14.9 to −12.6) with semaglutide (P<0.001) |
| Adverse events | Most commonly gastrointestinal and mostly mild to moderate in both groups; serious adverse events in 5% to 7% of tirzepatide groups and 3% of the semaglutide group | Most commonly gastrointestinal in both groups, and mostly mild to moderate |
What these trials can and cannot tell you. Both were open-label: participants and investigators knew which drug was given. Both were funded by the maker of one of the two drugs, and Lilly employees are among the authors. Each studied one population for a fixed time; their primary and key secondary measures were blood sugar, weight and waist size, not heart attacks, strokes or deaths. SURMOUNT-5 excluded people with type 2 diabetes; SURPASS-2 enrolled only people with it. In SURPASS-2, semaglutide was tested at a single level. In both trials tirzepatide was tested up to the highest level on its current US labels, while the highest semaglutide level tested is below the highest on the current Ozempic and Wegovy labels.
Other comparisons. A 117-person Lilly study (NCT03951753, Lancet Diabetes & Endocrinology, 2022) compared the two against placebo on insulin release and insulin sensitivity over 28 weeks. ClinicalTrials.gov also lists other randomised studies that give the two drugs to separate groups; each enrolled or plans fewer than 200 people (search of 18 November 2026). How to weigh trials like these: evidence grades.
05What do their labels warn about?
Boxed warning. Every US label for both drugs opens with a warning on thyroid C-cell tumours: in rodents for semaglutide, in rats for tirzepatide. For both, whether this happens in humans, including medullary thyroid carcinoma, is unknown, and both are contraindicated in people with a personal or family history of that cancer or with Multiple Endocrine Neoplasia syndrome type 2.
Warnings and precautions. The Wegovy and Zepbound labels list the same core set: acute pancreatitis, gallbladder disease, hypoglycaemia, acute kidney injury from fluid loss, severe gastrointestinal reactions, allergic reactions, diabetic retinopathy complications in type 2 diabetes, and pulmonary aspiration during anaesthesia or deep sedation. The Wegovy label also lists a raised heart rate. Both labels list reports after approval of necrotizing pancreatitis “sometimes resulting in death”. In January 2026 the MHRA said the UK product information for both had been updated on severe acute pancreatitis, “including rare reports of necrotising and fatal pancreatitis”. In February 2026 it said semaglutide “may be very rarely associated with” NAION, an eye condition that can cause vision loss. “Other GLP-1 agonists were not included in this review”, it added, and it “is reviewing any evidence for an association with other GLP-1 agonists”.
Most common adverse reactions. On both labels they are led by nausea, diarrhoea, vomiting, constipation and abdominal pain. Adverse-event rates from different trials are not directly comparable; the labels themselves say so. More: side effects, documented and unknown.
06Where do they stand on compounding, research labels and sport?
Compounding in the US. Both were on FDA’s drug shortage list from 2022, which loosened the limits on compounded copies. FDA declared the tirzepatide shortage resolved on 19 December 2024, after reconsidering a first decision of October 2024, and the semaglutide shortage on 21 February 2025. Its grace periods for copies then ended: for tirzepatide on 19 March 2025 for outsourcing facilities, and for semaglutide on 22 May 2025. On 1 April 2026 FDA said neither appears on its drug shortage list. Compounded drugs “are not FDA approved”, and by 31 May 2026 FDA had 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide. FDA says many resemble those for the approved versions, that the numbers are likely under-reported, and that “It is not always possible to determine if the adverse event directly resulted from use of the drug”.
Research-labelled products. FDA says it “has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption’”, and says these products, sold directly to consumers, are “of unknown quality and may be harmful to their health”. More: contamination and mislabeling.
Sport. Neither is named on WADA’s 2027 Prohibited List. WADA has placed both on its 2027 Monitoring Program, which follows substances it “wishes to monitor in order to detect potential patterns of misuse in sport”. On 21 September 2026 it said their status “will remain unchanged for 2027 pending further data becoming available on the possible effects on athletes who take them”. Anti-doping organisations decide how the List applies: peptides and anti-doping.
07What we don’t know
- How the two compare on heart attacks, strokes, kidney outcomes or death. ClinicalTrials.gov lists observational comparisons, which cannot replace a randomised trial; we found no randomised trial of one against the other on these outcomes (ClinicalTrials.gov and PubMed, 18 Nov 2026).
- How SURMOUNT-5’s result applies to people with type 2 diabetes, whom it excluded, or beyond 72 weeks.
- Whether an independent sponsor would find the same. Both published phase 3 comparisons were funded by Eli Lilly and were open-label.
- How either affects athletes. WADA is waiting for further data.
- What any product sold outside the licensed supply chain contains. FDA calls research-labelled versions of both “of unknown quality”.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.